Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Supraphysiological levels of GDF11 induce striated muscle atrophy.

Hammers DW, Merscham-Banda M, Hsiao JY, Engst S, Hartman JJ, Sweeney HL.

EMBO Mol Med. 2017 Apr;9(4):531-544. doi: 10.15252/emmm.201607231.

2.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, Zhao L, Vysotskaia V, Chu F, Bautista R, Cancilla B, Lamb P, Joly AH, Yakes FM.

Thyroid. 2013 Dec;23(12):1569-77. doi: 10.1089/thy.2013.0137. Epub 2013 Sep 17.

3.

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.

Forsyth T, Kearney PC, Kim BG, Johnson HW, Aay N, Arcalas A, Brown DS, Chan V, Chen J, Du H, Epshteyn S, Galan AA, Huynh TP, Ibrahim MA, Kane B, Koltun ES, Mann G, Meyr LE, Lee MS, Lewis GL, Noguchi RT, Pack M, Ridgway BH, Shi X, Takeuchi CS, Zu P, Leahy JW, Nuss JM, Aoyama R, Engst S, Gendreau SB, Kassees R, Li J, Lin SH, Martini JF, Stout T, Tong P, Woolfrey J, Zhang W, Yu P.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7653-8. doi: 10.1016/j.bmcl.2012.10.007. Epub 2012 Oct 16.

PMID:
23127890
4.

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.

Kim MH, Tsuhako AL, Co EW, Aftab DT, Bentzien F, Chen J, Cheng W, Engst S, Goon L, Klein RR, Le DT, Mac M, Parks JJ, Qian F, Rodriquez M, Stout TJ, Till JH, Won KA, Wu X, Yakes FM, Yu P, Zhang W, Zhao Y, Lamb P, Nuss JM, Xu W.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. doi: 10.1016/j.bmcl.2012.06.029. Epub 2012 Jun 16.

PMID:
22765894
5.

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).

Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S.

ACS Med Chem Lett. 2012 Apr 9;3(5):416-21. doi: 10.1021/ml300049d. eCollection 2012 May 10.

6.

Discovery of XL413, a potent and selective CDC7 inhibitor.

Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, Du H, Engst S, Ferguson K, Franzini M, Galan A, Holst CR, Huang P, Kane B, Kim MH, Li J, Markby D, Mohan M, Noson K, Plonowski A, Richards SJ, Robertson S, Shaw K, Stott G, Stout TJ, Young J, Yu P, Zaharia CA, Zhang W, Zhou P, Nuss JM, Xu W, Kearney PC.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. doi: 10.1016/j.bmcl.2012.04.024. Epub 2012 Apr 16. Erratum in: Bioorg Med Chem Lett. 2012 Aug 1;22(15):5157.

PMID:
22560567
7.

The design, synthesis, and biological evaluation of PIM kinase inhibitors.

Tsuhako AL, Brown DS, Koltun ES, Aay N, Arcalas A, Chan V, Du H, Engst S, Franzini M, Galan A, Huang P, Johnston S, Kane B, Kim MH, Laird AD, Lin R, Mock L, Ngan I, Pack M, Stott G, Stout TJ, Yu P, Zaharia C, Zhang W, Zhou P, Nuss JM, Kearney PC, Xu W.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3732-8. doi: 10.1016/j.bmcl.2012.04.025. Epub 2012 Apr 11.

PMID:
22542012
8.

Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.

Rice KD, Kim MH, Bussenius J, Anand NK, Blazey CM, Bowles OJ, Canne-Bannen L, Chan DS, Chen B, Co EW, Costanzo S, DeFina SC, Dubenko L, Engst S, Franzini M, Huang P, Jammalamadaka V, Khoury RG, Klein RR, Laird AD, Le DT, Mac MB, Matthews DJ, Markby D, Miller N, Nuss JM, Parks JJ, Tsang TH, Tsuhako AL, Wang Y, Xu W.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2693-7. doi: 10.1016/j.bmcl.2012.03.011. Epub 2012 Mar 10.

PMID:
22450127
9.

Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.

Bussenius J, Anand NK, Blazey CM, Bowles OJ, Bannen LC, Chan DS, Chen B, Co EW, Costanzo S, DeFina SC, Dubenko L, Engst S, Franzini M, Huang P, Jammalamadaka V, Khoury RG, Kim MH, Klein RR, Laird D, Le DT, Mac MB, Matthews DJ, Markby D, Miller N, Nuss JM, Parks JJ, Tsang TH, Tsuhako AL, Wang Y, Xu W, Rice KD.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2283-6. doi: 10.1016/j.bmcl.2012.01.105. Epub 2012 Feb 2.

PMID:
22342124
10.

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.

Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M.

Cancer Res. 2012 Jan 1;72(1):210-9. doi: 10.1158/0008-5472.CAN-11-1515. Epub 2011 Nov 14.

11.

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH.

Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16.

12.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.

Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6.

13.

Properties of p-cresol methylhydroxylase flavoprotein overproduced by Escherichia coli.

Engst S, Kuusk V, Efimov I, Cronin CN, McIntire WS.

Biochemistry. 1999 Dec 14;38(50):16620-8.

PMID:
10600124
14.
16.
18.
19.

Biochemical characterization of purified, human recombinant Lys304-->Glu medium-chain acyl-CoA dehydrogenase containing the common disease-causing mutation and comparison with the normal enzyme.

Kieweg V, Kräutle FG, Nandy A, Engst S, Vock P, Abdel-Ghany AG, Bross P, Gregersen N, Rasched I, Strauss A, Ghisla S.

Eur J Biochem. 1997 Jun 1;246(2):548-56.

20.

Characterization of medium-chain acyl-CoA dehydrogenase (MCAD) with a point mutation associated with MCAD deficiency.

Bross P, Jensen T, Kräutle F, Winter V, Andresen BS, Engst S, Bolund L, Kølvraa S, Ghisla S, Rasched I, et al.

Prog Clin Biol Res. 1992;375:473-8. No abstract available.

PMID:
1438390
21.

Alpha, beta-dehydrogenation by acyl-CoA dehydrogenases: role of functional groups at the active center.

Ghisla S, Engst S, Moll M, Bross P, Strauss AW, Kim JJ.

Prog Clin Biol Res. 1992;375:127-42. No abstract available.

PMID:
1438356
22.

Molecular characterization of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: identification of a lys329 to glu mutation in the MCAD gene, and expression of inactive mutant enzyme protein in E. coli.

Gregersen N, Andresen BS, Bross P, Winter V, Rüdiger N, Engst S, Christensen E, Kelly D, Strauss AW, Kølvraa S, et al.

Hum Genet. 1991 Apr;86(6):545-51.

PMID:
1902818
23.

Characterization of a disease-causing Lys329 to Glu mutation in 16 patients with medium-chain acyl-CoA dehydrogenase deficiency.

Gregersen N, Andresen BS, Bross P, Winter V, Rüdiger N, Engst S, Ghisla S, Christensen E, Kelly D, Strauss AW, et al.

J Inherit Metab Dis. 1991;14(3):314-6. No abstract available.

PMID:
1770781
24.

Characterization of wild-type and an active site mutant of human medium chain acyl-CoA dehydrogenase after expression in Escherichia coli.

Bross P, Engst S, Strauss AW, Kelly DP, Rasched I, Ghisla S.

J Biol Chem. 1990 May 5;265(13):7116-9.

Supplemental Content

Support Center